A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Exclusion Criteria

• •General Medical Exclusions:
• •Pregnant and lactating women
• •Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment, with the following exception: (1) hormone-replacement therapy or oral contraceptives; (2) tyrosine kinase inhibitors (TKIs) that have been discontinued greater than (\>) 7 days prior to Cycle 1, Day 1, baseline scans must be obtained after discontinuation of prior TKIs
• •Investigational therapy within 28 days prior to initiation of study treatment
• •History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
• •Known hypersensitivity or allergy to Chinese hamster ovary cell products or any component of the atezolizumab formulation
• •History of or active autoimmune disease
• •History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, risk of pulmonary toxicity, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
• •Prior allogeneic bone marrow transplantation or prior solid organ transplantation
• •History of human immunodeficiency virus (HIV)
• •Participants with active hepatitis B
• •Participants with active hepatitis C
• •Participants with active tuberculosis
• •Participants with a history of confirmed progressive multifocal leukoencephalopathy
• •Any serious medical condition, physical examination finding, or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study
• •Cancer-Specific Exclusions:
• •Active or untreated central nervous system (CNS) metastases, as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
• •Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \>/= 2 weeks prior to screening
• •Leptomeningeal disease
• •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently); participants with indwelling catheters are allowed.
• •Uncontrolled tumor-related pain
• •Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab
• •History of other malignancy within 2 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, localized prostate cancer treated with curative intent, ductal carcinoma in situ treated surgically with curative intent, or other cancers with a similar outcome
• •Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies (Note: Participants enrolled in the prior anti-PD-L1/PD-1 treated cohorts with melanoma may have received prior anti-cytotoxic T-lymphocyte-associated protein 4 treatment or other immunotherapies)
• •Treatment with systemic immunostimulatory agents within four weeks or five half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1
• •Treatment with systemic immunosuppressive medications within 2 weeks prior to Cycle 1, Day 1 (the use of inhaled corticosteroids and mineralocorticoids is allowed)
• •History of depression, suicidal ideation or behavior, bipolar disorder, or psychosis
• •Hypersensitivity to interferon alpha or any component of the product
• •Inadequately controlled hypertension
• •Prior history of hypertensive crisis or hypertensive encephalopathy
• •Significant vascular disease within 6 months prior to Day 1
• •History of hemoptysis
• •Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
• •History of tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1
• •Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding
• •Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure
• •Proteinuria, as demonstrated by urine dipstick or \> 1.0 gram of protein in a 24-hour urine collection
• •Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses of large volume
• •Hypersensitivity to obinutuzumab
• •Prior treatment with obinutuzumab